Filters
Improvements in overall survival (OS) and progression-free survival (PFS) were maintained with durvalumab in patients with unresectable stage III metastatic non-small cell lung cancer (NSCLC), according to updated results of the PACIFIC* trial presented at ASCO 2021.
Use of omalizumab for treating patients with severe allergic asthma in a real-world setting yields a steroid-sparing effect and helps minimize the occurrence of both clinically significant and severe asthma attacks, as reported in a study.
Patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 are at an increased risk of developing persistent COVID-19 and death, according to a retrospective study presented at EHA 2021.
Patient-related factors, such as sex, comorbidities, and medical history, affect the risk of early mortality in drug-resistant tuberculosis (DR-TB), reports a recent meta-analysis.
